Price Sensitivity and Information Barriers to the Take-up of Naloxone

This work was funded by the JPAL-North America Health Care Delivery Initiative. David Powell also thanks the CDC (R01CE02999) and NIDA (2P50DA046351-06A1) for financial support. Mireille Jacobson reports personal fees for serving as an expert witness for plaintiffs in lawsuits against opioid manufacturers and distributors outside the submitted work. This study was reviewed and deemed not human subjects by the Institutional Review Board at the University of Southern California. We thank participants at the American Economic Association Annual Meeting, the Stanford Health Economics Research Seminar, the UCSD Rady Seminar as well as Tom Chang, Rosalie Pacula, Sally Sadoff, and Anya Samek for helpful feedback on the design and interpretation of this experiment and James Lott, Candice Harden, and Emily Her for help implementing the study. The views expressed herein are those of the authors and do not necessarily reflect the views of the National Bureau of Economic Research.

• randomized controlled trials registry entry